Cart
sales@molnova.com
SGC-SMARCA-BRDVIII
CAS No. 1997319-84-2
SGC-SMARCA-BRDVIII( —— )
Catalog No. M28766 CAS No. 1997319-84-2
SGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 49 | In Stock |
|
| 5MG | 61 | In Stock |
|
| 10MG | 103 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 368 | In Stock |
|
| 100MG | 548 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1190 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSGC-SMARCA-BRDVIII
-
NoteResearch use only, not for human use.
-
Brief DescriptionSGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.
-
DescriptionSGC-SMARCA-BRDVIII is a potent and selective inhibitor of SMARCA2, SMARCA4, PB1(2), PB1(3) and PB1(5) with Kds of 35 nM, 36 nM, 3.7 μM, 2.0 μM and 13 nM, respectively.(In Vitro):SGC-SMARCA-BRDVIII blocks adipogenesis in 3T3-L1 murine fibroblasts.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorSCP1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1997319-84-2
-
Formula Weight371.43
-
Molecular FormulaC19H25N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (67.31 mM)
-
SMILESCC(C)(C)OC(N(CC1)CCN1c1c(N)nnc(-c(cccc2)c2O)c1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Medellin B, et al. Targeted Covalent Inhibition of Small CTD Phosphatase 1 to Promote the Degradation of the REST Transcription Factor in Human Cells. J Med Chem. 2022;65(1):507-519.
molnova catalog
related products
-
CCT077791
CCT077791 is a potent inhibitor of p300 and PCAF histone acetyltransferase activity for cancer research.
-
FHD-286
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
-
BRD7-IN-1
BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), forms PROTAC VZ185 via linkage to a VHL ligand, demonstrating potent activity against BRD7/9 with DC50 values of 4.5 and 1.8 nM, respectively .
